Veröffentlichungen
Hier finden sie wissenschaftliche Veröffentlichungen des BiKeR-Projektes in umgekehrt chronologischer Reihenfolge:
Update on malignancies in children with juvenile idiopathic arthritis in the German BIKER Registry.
Horneff G, Klein A, Oommen PT, Hospach A, Foeldvari I, Feddersen I, Minden K.
Clin Exp Rheumatol. 2016 Sep 8. [Epub ahead of print]
Safety and efficacy of etanercept and adalimumab in children aged 2 to 4 years with juvenile idiopathic arthritis.
Windschall D, Horneff G.
Clin Rheumatol. 2016 Oct 5. [Epub ahead of print]
Risk of serious infection in juvenile idiopathic arthritis patients associated with TNF-inhibitors and disease activity in the German BIKER registry.
Becker I, Horneff G.
Arthritis Care Res (Hoboken). 2016 Jul 7. doi: 10.1002/acr.22961. [Epub ahead of print]
Outcome and trends in treatment of systemic juvenile idiopathic arthritis in the German National Pediatric Rheumatological Database from 2000 to 2013.
Klotsche J, Raab A, Niewerth M, Sengler C, Ganser G, Kallinich T, Niehues T, Hufnagel M, Thon A, Hospach T, Horneff G, Minden K.
Arthritis Rheumatol. 2016 Jun 22. doi: 10.1002/art.39796. [Epub ahead of print]
Biologic-associated infections in pediatric rheumatology.
Horneff G.
Curr Rheumatol Rep. 2015 Nov;17(11):66. doi: 10.1007/s11926-015-0542-z. Review.
Inflammatory Bowel Disease in Juvenile Idiopathic Arthritis Patients Treated with Biologics.
Barthel D, Ganser G, Kuester RM, Onken N, Minden K, Girschick HJ, Hospach A, Horneff G.
J Rheumatol. 2015 Nov;42(11):2160-5. doi: 10.3899/jrheum.140472.
MRP8/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis.
Anink J, Van Suijlekom-Smit LW, Otten MH, Prince FH, van Rossum MA, Dolman KM, Hoppenreijs EP, ten Cate R, Ursu S, Wedderburn LR, Horneff G, Frosch M, Vogl T, Gohar F, Foell D, Roth J, Holzinger D.
Arthritis Res Ther. 2015 Aug 7;17:200. doi: 10.1186/s13075-015-0723-1.
Safety of biologic therapies for the treatment of juvenile idiopathic arthritis.
Horneff G.
Expert Opin Drug Saf. 2015 Jul;14(7):1111-26. doi: 10.1517/14740338.2015.1042453. Review.
Uveitis Events During Adalimumab, Etanercept, and Methotrexate Therapy in Juvenile Idiopathic Arthritis: Data From the Biologics in Pediatric Rheumatology Registry.
Foeldvari I, Becker I, Horneff G.
Arthritis Care Res (Hoboken). 2015 Nov;67(11):1529-35. doi: 10.1002/acr.22613.
Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA).
Klotsche J, Niewerth M, Haas JP, Huppertz HI, Zink A, Horneff G, Minden K.
Ann Rheum Dis. 2015 Apr 29. pii: annrheumdis-2014-206747. doi: 10.1136/annrheumdis-annrheumdis-2014-206747
Incidence of herpes zoster infections in juvenile idiopathic arthritis patients.
Nimmrich S, Horneff G.
Rheumatol Int. 2015 Mar;35(3):465-70. doi: 10.1007/s00296-014-3197-6. Epub 2015 Jan 13
[Current news from the BIKER register].
Horneff G, Minden K, Foeldvari I, Onken N, Windschall D, Hospach A, Ganser G, Klotsche J, Becker I; BIKER-Register Studiengruppe.
Z Rheumatol. 2014 Dec;73(10):897-906. doi: 10.1007/s00393-014-1397-9. German.
Safety and efficacy of etanercept in children with juvenile idiopathic arthritis below the age of 2 years.
Windschall D, Müller T, Becker I, Horneff G.
Rheumatol Int. 2015 Apr;35(4):613-8. doi: 10.1007/s00296-014-3125-9. Epub 2014 Sep 11.
Predictors of response to methotrexate in juvenile idiopathic arthritis.
Albarouni M, Becker I, Horneff G.
Pediatr Rheumatol Online J. 2014 Aug 13;12:35. doi: 10.1186/1546-0096-12-35. eCollection 2014.
Safety and efficacy of etanercept in children with the JIA categories extended oligoarthritis, enthesitis-related arthritis and psoriasis arthritis.
Windschall D, Müller T, Becker I, Horneff G.
Clin Rheumatol. 2015 Jan;34(1):61-9. doi: 10.1007/s10067-014-2744-6. Epub 2014 Jul 18.
[Therapy of juvenile idiopathic arthritis in early adulthood with biologics: transition from pediatric to adult care].
Niewerth M, Minden K, Klotsche J, Horneff G.
Z Rheumatol. 2014 Aug;73(6):532-40. doi: 10.1007/s00393-014-1378-z. German.
Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry.
Schmeling H, Minden K, Foeldvari I, Ganser G, Hospach T, Horneff G.
Arthritis Rheumatol. 2014 Sep;66(9):2580-9. doi: 10.1002/art.38741.
Definition of improvement in juvenile idiopathic arthritis using the juvenile arthritis disease activity score.
Horneff G, Becker I.
Rheumatology (Oxford). 2014 Jul;53(7):1229-34. doi: 10.1093/rheumatology/ket470. Epub 2014 Mar 4.
Predictors of response to etanercept in polyarticular-course juvenile idiopathic arthritis.
Geikowski T, Becker I, Horneff G; German BIKER Registry Collaborative Study Group.
Rheumatology (Oxford). 2014 Jul;53(7):1245-9. doi: 10.1093/rheumatology/ket490. Epub 2014 Mar 4.
Improvement in health-related quality of life for children with juvenile idiopathic arthritis after start of treatment with etanercept.
Klotsche J, Minden K, Thon A, Ganser G, Urban A, Horneff G.
Arthritis Care Res (Hoboken). 2014 Feb;66(2):253-62. doi: 10.1002/acr.22112
Efficacy and safety of oral and parenteral methotrexate therapy in children with juvenile idiopathic arthritis: an observational study with patients from the German Methotrexate Registry.
Klein A, Kaul I, Foeldvari I, Ganser G, Urban A, Horneff G.
Arthritis Care Res (Hoboken). 2012 Sep;64(9):1349-56. doi: 10.1002/acr.21697
Development of inflammatory bowel disease in patients with juvenile idiopathic arthritis treated with etanercept.
van Dijken TD, Vastert SJ, Gerloni VM, Pontikaki I, Linnemann K, Girschick H, Armbrust W, Minden K, Prince FH, Kokke FT, Nieuwenhuis EE, Horneff G,WulffraatNM.
J Rheumatol. 2011 Jul;38(7):1441-6. Epub 2011 Apr 1.
Report on malignancies in the German juvenile idiopathic arthritis registry.
Horneff G, Foeldvari I,Minden K, Moebius D, Hospach T.
Rheumatology (Oxford). 2011 Jan;50(1):230-6.
Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis.
Papsdorf V, Horneff G.
Rheumatology (Oxford). 2011 Jan;50(1):214-21. Erratum in: Rheumatology (Oxford). 2011 Apr;50(4):814
Malignancy and tumor necrosis factor inhibitors in juvenile idiopathic arthritis.
Horneff G.
Z Rheumatol. 2010 Aug;69(6):516-26. Review. German.
Updated statement by the German Society for Pediatric and Adolescent Rheumatology (GKJR) on the FDA's report regarding malignancies in anti-TNF-treated patients from Aug. 4, 2009.
Horneff G, Hospach T, Dannecker G, Föll D, Haas JP, Girschick HJ, Huppertz HI, Keitzer R, Laws HJ, Michels H, Minden K, Trauzeddel R.
Z Rheumatol. 2010 Aug;69(6):561-7. German.
Safety and efficacy of once weekly etanercept 0.8 mg/kg in a multicentre 12 week trial in active polyarticular course juvenile idiopathic arthritis.
Horneff G, Ebert A, Fitter S, Minden K, Foeldvari I, Kümmerle-Deschner J, Thon A, Girschick HJ, Weller F, Huppertz HI.
Rheumatology (Oxford). 2009 Aug;48(8):916-9. Epub 2009 May 29.
Improvement of functional ability in children with juvenile idiopathic arthritis by treatment with etanercept.
Halbig M, Horneff G.
Rheumatol Int. 2009 Dec;30(2):229-38
Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry.
Horneff G, De Bock F, Foeldvari I, Girschick HJ, Michels H, Moebius D, Schmeling H; German and Austrian Paediatric Rheumatology Collaborative Study Group.
Ann Rheum Dis. 2009 Apr;68(4):519-25. Epub 2008 Apr 15
Safety and efficacy of etanercept in children with juvenile idiopathic arthritis below the age of 4 years.
Tzaribachev N, Kuemmerle-Deschner J, Eichner M, Horneff G.
Rheumatol Int. 2008 Aug;28(10):1031-4. Epub 2008 Mar 28
Safety and efficacy of once-weekly application of Etanercept in children with juvenile idiopathic arthritis.
Kuemmerle-Deschner JB, Horneff G.
Rheumatol Int. 2007 Dec;28(2):153-6. Epub 2007 Jul 20.
Etanercept and uveitis in patients with juvenile idiopathic arthritis.
Schmeling H, Horneff G.
Rheumatology (Oxford). 2005 Aug;44(8):1008-11. Epub 2005 Apr 26
The German etanercept registry for treatment of juvenile idiopathic arthritis.
Horneff G, Schmeling H, Biedermann T, Foeldvari I, Ganser G, Girschick HJ, Hospach T, Huppertz HI, Keitzer R, Küster RM, Michels H, Moebius D, Rogalski B, Thon A; Paediatric Rheumatology Collaborative Group.
Ann Rheum Dis. 2004 Dec;63(12):1638-44. Epub 2004 Apr 28. Review.